CL2010001624A1 - Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto. - Google Patents

Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto.

Info

Publication number
CL2010001624A1
CL2010001624A1 CL2010001624A CL2010001624A CL2010001624A1 CL 2010001624 A1 CL2010001624 A1 CL 2010001624A1 CL 2010001624 A CL2010001624 A CL 2010001624A CL 2010001624 A CL2010001624 A CL 2010001624A CL 2010001624 A1 CL2010001624 A1 CL 2010001624A1
Authority
CL
Chile
Prior art keywords
bisphenol diglycidyl
pharmaceutical composition
compounds
prostate cancer
compound
Prior art date
Application number
CL2010001624A
Other languages
English (en)
Spanish (es)
Inventor
Marianne D Sadar
Jun Wang
Mike Leblanc
Nasrin R Mawki
Raymondj Andersen
David E Williams
Original Assignee
Univ British Columbia
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41465435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001624(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ British Columbia, British Columbia Cancer Agency Branch filed Critical Univ British Columbia
Publication of CL2010001624A1 publication Critical patent/CL2010001624A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CL2010001624A 2008-07-02 2010-12-30 Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto. CL2010001624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12953708P 2008-07-02 2008-07-02

Publications (1)

Publication Number Publication Date
CL2010001624A1 true CL2010001624A1 (es) 2011-09-16

Family

ID=41465435

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001624A CL2010001624A1 (es) 2008-07-02 2010-12-30 Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto.

Country Status (21)

Country Link
US (3) US9862667B2 (https=)
EP (2) EP3252032A1 (https=)
JP (3) JP2011526250A (https=)
KR (3) KR20110044216A (https=)
CN (2) CN105012282A (https=)
AU (1) AU2009266379C1 (https=)
BR (1) BRPI0913673A2 (https=)
CA (1) CA2728219C (https=)
CL (1) CL2010001624A1 (https=)
CO (1) CO6351774A2 (https=)
DK (1) DK2307342T3 (https=)
ES (1) ES2640003T3 (https=)
HK (1) HK1216608A1 (https=)
HU (1) HUE034458T2 (https=)
IL (1) IL210120A (https=)
MX (1) MX2010014372A (https=)
NZ (1) NZ589759A (https=)
RU (2) RU2572596C2 (https=)
TR (1) TR201011157T1 (https=)
WO (1) WO2010000066A1 (https=)
ZA (1) ZA201100507B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034458T2 (en) 2008-07-02 2018-02-28 British Columbia Cancer Agency Branch Diglycidyl ether derivatives, therapeutics and methods for their use
WO2011040421A1 (ja) 2009-09-29 2011-04-07 武田薬品工業株式会社 スクリーニング方法
JP5375502B2 (ja) * 2009-10-06 2013-12-25 信越化学工業株式会社 アルコール性水酸基含有化合物及びその製造方法
US20130109758A1 (en) * 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
US9388112B2 (en) 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
JP5892949B2 (ja) 2010-02-10 2016-03-23 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ビフェニル置換環状ケトエノール類
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHOD FOR THEIR USE
WO2012145330A1 (en) * 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2012145328A1 (en) * 2011-04-18 2012-10-26 The University Of British Columbia Dibenzylphenyl compounds and methods for their use
US8533714B2 (en) 2011-05-03 2013-09-10 International Business Machines Corporation Dynamic virtual machine domain configuration and virtual machine relocation management
US20130045204A1 (en) * 2011-08-19 2013-02-21 The University Of British Columbia Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) * 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US9365510B2 (en) * 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
BR112015008936A2 (pt) * 2012-11-02 2017-07-04 Seiwa Kasei Co Ltd derivado de éter de propilfenila, e um inibidor de produção de melanina, um agente de branqueamento, um agente antibacteriano e um cosmético contendo o mesmo
AU2014262333B2 (en) * 2013-05-10 2016-06-16 British Columbia Cancer Agency Branch Ester derivatives of androgen receptor modulators and methods for their use
WO2015031984A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
WO2016058080A1 (en) * 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch Fluoro-chloro bisphenol ether compounds and methods for their use
DK3988541T3 (da) 2015-01-13 2024-09-16 British Columbia Cancer Agency Branch Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US12415939B2 (en) * 2015-09-30 2025-09-16 The Regents Of The University Of California Nano-adhesive and surface primer compound and use thereof
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途
CN113666806A (zh) * 2020-05-15 2021-11-19 上海安谱实验科技股份有限公司 一种双酚f 2,3-二羟丙基(2-氯-1-丙基)乙醚的制备方法
WO2023046283A1 (en) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity
TWI874822B (zh) * 2022-09-23 2025-03-01 上緯創新育成股份有限公司 降解酸酐環氧固化物的方法、其製備的多元醇以及熱固性樹脂
CN121652089A (zh) * 2024-09-11 2026-03-13 中国海洋大学 一种ntd抑制剂及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2571217A (en) * 1951-10-16 Horace s
US2890189A (en) 1954-06-14 1959-06-09 Johnson & Son Inc S C Alkali soluble resins and compositions containing the same
US3162615A (en) 1961-01-03 1964-12-22 Dow Chemical Co Polyesters from cyclic polyhaloalkane polyols and unsaturated dicarboxylic acids
FR1389005A (fr) 1963-01-09 1965-02-12 Bayer Ag Procédé perfectionné pour durcir des polyépoxydes
US4284574A (en) 1979-06-15 1981-08-18 Ciba-Geigy Corporation Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them
US4369298A (en) 1980-05-27 1983-01-18 Tokuyama Soda Kabushiki Kaisha Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers
DE3170223D1 (en) 1981-01-13 1985-06-05 Teijin Ltd Ion-permeable composite membrane and its use in selective separation
PL141793B1 (en) 1984-10-08 1987-08-31 Politechnika Warszawska Method of obtaining bisphenolic resins
US5753730A (en) * 1986-12-15 1998-05-19 Mitsui Toatsu Chemicals, Inc. Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby
JPH0832844B2 (ja) 1987-02-09 1996-03-29 パイロツトインキ株式会社 筆記板用不透明性インキ
DE3852839T2 (de) * 1987-04-27 1995-06-22 Mitsubishi Gas Chemical Co Hitzehärtbare Harzzusammensetzung.
KR910003821B1 (ko) 1987-06-01 1991-06-12 더 다우 케미칼 캄파니 하이드록시방향족 화합물의 프로파르길 에테르를 제조하는 방법
US5155196A (en) * 1987-06-01 1992-10-13 The Dow Chemical Company Polymer resulting from the cure of a preformed chromene-containing mixture
DE3821585A1 (de) 1987-09-13 1989-03-23 Hoechst Ag Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung
US4855184A (en) 1988-02-02 1989-08-08 Minnesota Mining And Manufacturing Company Radiation-curable protective coating composition
DE3939760A1 (de) * 1989-12-01 1991-06-06 Bayer Ag Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern
EP0515128A1 (en) 1991-05-23 1992-11-25 Konica Corporation Silver halide color photographic light-sensitive material
JPH0649473A (ja) 1992-08-04 1994-02-22 Asahi Chem Ind Co Ltd 冷媒組成物
DE4323512A1 (de) 1992-09-01 1994-04-28 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
CN1167437A (zh) 1994-11-29 1997-12-10 赫彻斯特马里恩鲁斯公司 用三芳基-乙烯衍生物治疗和预防骨质疏松的方法
DE19526146A1 (de) 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JPH09176240A (ja) 1995-12-27 1997-07-08 Mitsubishi Chem Corp 光重合性組成物
JPH10133427A (ja) 1996-11-05 1998-05-22 Fuji Xerox Co Ltd 静電潜像現像用キャリア、静電潜像現像剤及び画像形成方法
AR011626A1 (es) * 1997-02-07 2000-08-30 Shell Int Research Un procedimiento para la elaboracion de compuestos epoxidos, resinas epoxidas obtenidas mediante dicho procedimiento y un procedimiento para laelaboracion de compuestos intermedios para la elaboracion de compuestos epoxidos
JPH10316803A (ja) * 1997-05-16 1998-12-02 Teijin Chem Ltd 難燃性樹脂組成物
IL125840A (en) 1997-08-22 2002-12-01 Teijin Chemicals Ltd Bromine compound production method
JPH11166087A (ja) 1997-12-04 1999-06-22 Teijin Chem Ltd 難燃性樹脂組成物
CA2302169A1 (en) 1998-06-30 2000-01-13 The University Of British Columbia Inhibitors of androgen-independent activation of androgen receptor
US6245117B1 (en) 1998-08-07 2001-06-12 Ipposha Oil Industries Co., Ltd. Modifier of cellulose fibers and modification method of cellulose fibers
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
JP3795679B2 (ja) 1998-09-01 2006-07-12 帝人化成株式会社 臭素化合物の製造方法
AU775928B2 (en) * 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US6534621B2 (en) * 2000-05-18 2003-03-18 Dow Global Technologies Inc. Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
AU2001286965A1 (en) * 2000-08-31 2002-03-13 Advanced Medicine, Inc. Sodium channel modulators
US6646102B2 (en) 2001-07-05 2003-11-11 Dow Global Technologies Inc. Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
AU2003217304A1 (en) 2002-02-28 2003-09-16 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
MXPA05002168A (es) * 2002-08-27 2005-05-23 Galderma Res & Dev Analogos de vitamina d.
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US7595345B2 (en) 2003-11-20 2009-09-29 Eli Lilly And Company Vitamin D receptor modulators
JP2007524677A (ja) 2004-02-13 2007-08-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 放射性標識化合物及び組成物、それらの前駆体及びそれらの製造方法
JP2005325301A (ja) 2004-05-17 2005-11-24 Fuji Photo Film Co Ltd セルロースアシレートドープ組成物、およびセルロースアシレートフィルム
US20090105349A1 (en) 2004-08-18 2009-04-23 Warner-Lambert Company Llc Androgen modulators
JP2006208607A (ja) 2005-01-26 2006-08-10 Fuji Photo Film Co Ltd パターン形成材料、並びにパターン形成装置及び永久パターン形成方法
JP4753601B2 (ja) 2005-03-23 2011-08-24 旭化成イーマテリアルズ株式会社 感光性組成物
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
JP2007290980A (ja) * 2006-04-21 2007-11-08 Shin Etsu Chem Co Ltd 含フッ素（メタ）アクリル酸エステル
TW200819421A (en) 2006-10-31 2008-05-01 Univ Nat Chunghsing The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste
KR20090115797A (ko) 2007-02-20 2009-11-06 바스프 에스이 고굴절률 단량체, 이의 조성물 및 용도
HUE034458T2 (en) 2008-07-02 2018-02-28 British Columbia Cancer Agency Branch Diglycidyl ether derivatives, therapeutics and methods for their use
US20130109758A1 (en) 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
US9388112B2 (en) 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHOD FOR THEIR USE
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
WO2012145328A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Dibenzylphenyl compounds and methods for their use
US20130045204A1 (en) 2011-08-19 2013-02-21 The University Of British Columbia Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
AU2014262333B2 (en) 2013-05-10 2016-06-16 British Columbia Cancer Agency Branch Ester derivatives of androgen receptor modulators and methods for their use
CN103342892A (zh) 2013-06-06 2013-10-09 西安交通大学 一种双马来酰亚胺树脂的增韧改性剂及其制备方法
US20150010469A1 (en) 2013-07-03 2015-01-08 British Columbia Cancer Agency Branch Bisphenol ether compounds with novel bridging groups and methods for their use
WO2015031984A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
WO2016058080A1 (en) 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch Fluoro-chloro bisphenol ether compounds and methods for their use
WO2016058082A1 (en) 2014-10-14 2016-04-21 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
DK3988541T3 (da) 2015-01-13 2024-09-16 British Columbia Cancer Agency Branch Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same

Also Published As

Publication number Publication date
WO2010000066A1 (en) 2010-01-07
KR101719550B1 (ko) 2017-03-24
CN102083780B (zh) 2017-03-29
JP2015163615A (ja) 2015-09-10
DK2307342T3 (en) 2017-10-02
CA2728219C (en) 2016-12-13
JP6190025B2 (ja) 2017-08-30
US8686050B2 (en) 2014-04-01
EP3252032A1 (en) 2017-12-06
IL210120A0 (en) 2011-02-28
KR20110044216A (ko) 2011-04-28
RU2015107733A (ru) 2015-06-27
JP2011526250A (ja) 2011-10-06
AU2009266379B2 (en) 2015-01-15
RU2015107733A3 (https=) 2018-10-30
JP6023250B2 (ja) 2016-11-09
JP2017039747A (ja) 2017-02-23
HUE034458T2 (en) 2018-02-28
IL210120A (en) 2015-06-30
KR20150038226A (ko) 2015-04-08
ES2640003T3 (es) 2017-10-31
RU2572596C2 (ru) 2016-01-20
KR101717098B1 (ko) 2017-03-16
BRPI0913673A2 (pt) 2015-10-13
TR201011157T1 (tr) 2011-10-21
US20170121261A1 (en) 2017-05-04
EP2307342A1 (en) 2011-04-13
RU2011103538A (ru) 2012-08-10
US20110230556A1 (en) 2011-09-22
HK1216608A1 (zh) 2016-11-25
EP2307342A4 (en) 2011-07-20
CN102083780A (zh) 2011-06-01
ZA201100507B (en) 2013-03-27
EP2307342B1 (en) 2017-06-21
AU2009266379A1 (en) 2010-01-07
US20130245129A1 (en) 2013-09-19
MX2010014372A (es) 2011-06-20
KR20160065996A (ko) 2016-06-09
US9862667B2 (en) 2018-01-09
NZ589759A (en) 2012-12-21
AU2009266379C1 (en) 2016-12-22
CO6351774A2 (es) 2011-12-20
CN105012282A (zh) 2015-11-04
CA2728219A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
CL2010001624A1 (es) Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto.
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2021011826A (es) Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
PH12018502500A1 (en) Methods and compositions for determining resistance to androgen receptor therapy
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CO6630103A2 (es) Fitocanabinoides en el tratamiento de cáncer
CL2008002982A1 (es) Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2011002648A1 (es) Composicion topica que comprende un compuesto derivado de 1,2,4-tiadiazol o tiourea, un agente modificador de la viscosidad, un conservante y agua; estuche para la composicion; metodo para preparar la composicion; y uso para tratar una enfermedad o trastorno dermatologico mediado por un receptor de melanocortina tal como acne.
BR112012021296A2 (pt) imunoconjugados e anticorpos de receptor de folato 1 e usos dos mesmos.
CL2013003227A1 (es) “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct
CL2008001815A1 (es) Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2013000722A1 (es) Compuestos derivados de eteno sustituidos con 3 anillos, o un n-oxido o una sal del mismo, moduladores de receptores de estrogenos; composicion farmaceutica; y su uso para el tratamiento del cancer tal como el cancer de mama y de prostata, migraña, artritis, obesidad, alzheimer, parkinson y psicosis, entre otras enfermedades.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
BR112015023098A2 (pt) agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
FI20115135L (fi) Mikrofibrilloitu selluloosa käytettäväksi erityisesti atooppisen ihotulehduksen ja psoriasiksen hoidossa
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
BR112013003579A2 (pt) adenovírus, células, e, métodos para tratar câncer
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
BR112015026257A2 (pt) terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata